Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

NCT03070691 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Basal Cell Carcinoma

Interventions

DRUG: LDE225B
DRUG: Vehicle

Sponsor

Novartis Pharmaceuticals